Indeglitazar - 10mM in DMSO , Peroxisome proliferator-activated receptor agonist, CAS No.835619-41-5, Peroxisome proliferator-activated receptor agonist

CAS: 835619-41-5 Cat. No.: I655958 分子式: C19H19NO6S 分子量: 389.42 PubChem CID: 11395145
注文可能
GRADE & PURITY 10mM in DMSO
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
Size
USA
ドイツ (EU)*
Price
Qty
1ml
I655958-1ml
受注生産 · 8~12週間
$115.90
Enter a quantity for the sizes you want to add.
🧪

Why this grade

10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

概要

Indeglitazar (PPM 204) is an orally available PPAR pan-agonist for all three PPARα , PPARδ and PPARγ

In Vitro

In an assay of preadipocyte differentiation, measuring in part functional insulin sensitization capability of the cells, Indeglitazar shows an EC 50 of 0.32 μM compared with Rosiglitazone, which shows an EC 50 of 13 nM, although the maximal response obtained from the 2 compounds is comparable. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

An initial assessment of in vivo activity is carried out using the Zucker rat model of diabetes. The significant lowering of glucose, HbA 1C , triglycerides, and total cholesterol are observed after i.v. treatment with 10 mg/kg Indeglitazar once per day for 3 weeks. Notably, the level of Adiponectin (on day 21) is essentially unchanged in treated vs. untreated animals (4.8 mcg/mL vs. 4.9 mcg/mL), thus the observed reductions in glucose and HbA 1C are achieved in an adiponectin-independent fashion. These differences in the effects of Indeglitazar in vivo may be a consequence of synergy between the 3 PPAR activities or because of the SPPARM profile of the compound, or a combination of these factors. The oral activity of Indeglitazar is assessed in the ob/ob model of diabetes and insulin resistance. Indeglitazar significantly decreases glucose, insulin, triglycerides, and free fatty acid levels . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IC50& Target:PPARα PPARδ PPARγ

Specifications

仕様と純度
10mM in DMSO
生化学的・生理学的メカニズム
Indeglitazar (PPM 204) is an orally available PPAR pan-agonist for all three PPARα , PPARδ and PPARγ.
保管条件
Store at -80°C
入荷
Dry ice packs + Cold packs
この製品は冷冷この冷このこの製品の運送が必要です。地上およびその他の経済サービスは利用できません。
アクションタイプ
AGONIST
作用メカニズム
Peroxisome proliferator-activated receptor agonist
製品の性質
ALogP2.9
名前と識別子
異性体SMILES COC1=CC=C(C=C1)S(=O)(=O)N2C=C(C3=C2C=CC(=C3)OC)CCC(=O)O
PubChem CID 11395145
分子量 389.42

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

証明書(CoA、COO、BSE/TSEと分析図)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
ソリューション計算機
レビュー

顧客レビュー

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.